MDR- and CYP3A4-mediated drug-herbal interactions

Life Sciences

Volumn 78, Issue 18, 2006, Pages 2131-2145

  Pal, Dhananjay ^a   Mitra, Ashim K ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Biovailability; CYP3A4; Drug; Drug resistance; Herbs; P gp

Indexed keywords

ACETYLSALICYLIC ACID; ALPRAZOLAM; AMITRIPTYLINE; AMPRENAVIR; ANTIVIRUS AGENT; BENZODIAZEPINE DERIVATIVE; CYCLOSPORIN; CYTOCHROME P450 3A; DIGOXIN; FEXOFENADINE; GLYCOPROTEIN P; HERBACEOUS AGENT; HYPERICIN; HYPERICUM REVOLUTUM EXTRACT; INDINAVIR; INDONAVIR; IRINOTECAN; KAEMPFEROL; LOPINAVIR; MIDAZOLAM; MIDAZOLAN; ORAL CONTRACEPTIVE AGENT; PHENPROCOUMON; QUERCETIN; RITONAVIR; SAQUINAVIR; SILIBININ; THEOPHYLLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALCOHOL METABOLISM; ANXIETY DISORDER; AREA UNDER THE CURVE; BLEEDING; BRAIN HEMORRHAGE; CONFERENCE PAPER; DEPRESSION; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG HYPERSENSITIVITY; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HYPERTENSION; IN VITRO STUDY; NONHUMAN; SKIN INFLAMMATION; STEADY STATE; TREATMENT FAILURE; UNWANTED PREGNANCY;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; GENES, MDR; HUMANS; PHARMACEUTICAL PREPARATIONS; PLANT PREPARATIONS;

HYPERICUM;

EID: 33644891064     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2005.12.010     Document Type: Conference Paper

References (172)

1. M. Agrosi, S. Mischiatti, P.C. Harrasser, and D. Savio Oral bioavailability of active principles from herbal products in humans. A study on Hypericum perforatum extracts using the soft gelatin capsule technology Phytomedicine 7 6 2000 455 462
2. S.V. Ambudkar, S. Dey, C.A. Hrycyna, M. Ramachandra, I. Pastan, and M.M. Gottesman Biochemical, cellular, and pharmacological aspects of the multidrug transporter Annu. Rev. Pharmacol. Toxicol. 39 1999 361 398
3. S.V. Ambudkar, C. Kimchi-Sarfaty, Z.E. Sauna, and M.M. Gottesman P-glycoprotein: from genomics to mechanism Oncogene 22 47 2003 7468 7485
4. J.A. Astin Why patients use alternative medicine: results of a national study JAMA 279 19 1998 1548 1553
5. A. Ayrton, and P. Morgan Role of transport proteins in drug absorption, distribution and excretion Xenobiotica 31 8-9 2001 469 497
6. D.G. Bailey, J. Malcolm, O. Arnold, and J.D. Spence Grapefruit juice-drug interactions Br. J. Clin. Pharmacol. 46 2 1998 101 110
7. D.M. Barbenel, B. Yusufi, D. O'Shea, and C.J. Bench Mania in a patient receiving testosterone replacement postorchidectomy taking St. John's wort and sertraline J. Psychopharmacol. 14 1 2000 84 86
8. G.W. Barone, B.J. Gurley, and S.R. Abul-Ezz Herbal supplements: a potential for drug interactions in transplant recipients Transplatation 71 2001 239 241
9. S.E. Bates, S.J. Currier, M. Alvarez, and A.T. Fojo Modulation of P-glycoprotein phosphorylation and drug transport by sodium butyrate Biochemistry 31 28 1992 6366 6372
10. S.E. Bates, R. Robey, K. Miyake, K. Rao, D.D. Ross, and T. Litman The role of half-transporters in multidrug resistance J. Bioenerg. Biomembr. 33 6 2001 503 511
11. S. Bauer, E. Stormer, A. Johne, H. Kruger, K. Budde, H.H. Neumayer, I. Roots, and I. Mai Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients Br. J. Clin. Pharmacol. 55 2003 203 211
12. S.E. Beckman, R.W. Sommi, and J. Switzer Consumer use of St. John's wort: a survey on effectiveness, safety, and tolerability Pharmacotherapy 20 5 2000 568 574
13. A. Biber, H. Fischer, A. Romer, and S.S. Chatterjee Oral bioavailability of hyperforin from hypericum extracts in rats and human volunteers Pharmacopsychiatry 31 Suppl. 1 1998 36 43
14. K. Bogman, A.K. Peyer, M. Torok, E. Kusters, and J. Drewe HMG-CoA reductase inhibitors and P-glycoprotein modulation Br. J. Pharmacol. 132 6 2001 1183 1192
15. S. Bon, K. Hartmann, and M. Kubn Johanniskraut: ein enzymindultor? Schweitzer Apothekerzeitung 16 1999 535 536
16. C. Bokemeyer, L.M. Fels, T. Dunn, W. Voigt, J. Gaedeke, H.J. Schmoll, H. Stolte, and H. Lentzen Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour activity Br. J. Cancer 74 2 1996 2036 2041
17. A. Bordia, S.K. Verma, and K.C. Srivastava Effect of garlic (Allium sativum) on blood lipids, blood sugar, fibrinogen and fibrinolytic activity in patients with coronary artery disease Prostaglandins Leukot. Essent. Fat. Acids 58 4 1998 257 263
18. P. Borst, R. Evers, M. Kool, and J. Wijnholds A family of drug transporters: the multidrug resistance-associated proteins J. Natl. Cancer Inst. 92 16 2000 1295 1302
19. B.J. Bray, N.B. Perry, D.B. Menkes, and R.J. Rosengren St. John's wort extract induces CYP3A and CYP2E1 in the Swiss Webster mouse Toxicol. Sci. 66 1 2002 27 33
20. T. Breidenbach, M.W. Hoffmann, T. Becker, H. Schlitt, and J. Klempnauer Drug interaction of St. John's wort with cyclosporin Lancet 355 9218 2000 1912
21. T. Breidenbach, V. Kliem, M. Burg, J. Radermacher, M.W. Hoffmann, and J. Klempnauer Profound drop of cyclosporin A whole blood trough levels caused by St. John's wort (Hypericum perforatum) Transplantation 69 2000 2229 2230
22. F. Brinker Herb Contraindications and Drug Interactions 1998 Eclectic Medical Publications Sandy, Oregan
23. B.E. Burnham Garlic as a possible risk for post-operative bleeding Plastic Reconstr. Surg. 95 1995 213 219
24. P.M. Chaudhary, and I.B. Roninson Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs J. Natl. Cancer Inst. 85 8 1993 632 639
25. M.L. Chavez, and P.I. Chavez Ginkgo (part 1): history, use, and pharmacologic properties Hosp. Pharm. 33 1998 658 672
26. C.J. Chen, J.E. Chin, K. Ueda, D.P. Clark, I. Pastan, M.M. Gottesman, and I.B. Roninson Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells Cell 47 3 1986 381 389
27. M. Chiba, M. Hensleigh, J.A. Nishime, S.K. Balani, and J.H. Lin Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor Drug Metab. Dispos. 24 3 1996 307 314
28. E. Chieli, N. Romiti, F. Cervelli, and R. Tongiani Effects of flavonols on P-glycoprotein activity in cultured rat hepatocytes Life Sci. 57 19 1995 1741 1751
29. K.V. Chin, S.S. Chauhan, I. Pastan, and M.M. Gottesman Regulation of mdr RNA levels in response to cytotoxic drugs in rodent cells Cell Growth Differ. 1 8 1990 361 365
30. K.V. Chin, S. Tanaka, G. Darlington, I. Pastan, and M.M. Gottesman Heat shock and arsenite increase expression of the multidrug resistance (MDR1) gene in human renal carcinoma cells J. Biol. Chem. 265 1 1990 221 226
31. K.V. Chin, K. Ueda, I. Pastan, and M.M. Gottesman Modulation of activity of the promoter of the human MDR1 gene by Ras and p53 Science 255 5043 1992 459 462
32. W.L. Chiou, S.M. Chung, and T.C. Wu Potential role of P-glycoprotein in affecting hepatic metabolism of drugs Pharm. Res. 17 8 2000 903 905
33. S.P. Cole, G. Bhardwaj, J.H. Gerlach, J.E. Mackie, C.E. Grant, K.C. Almquist, A.J. Stewart, E.U. Kurz, A.M. Duncan, and R.G. Deeley Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line Science 258 5088 1992 1650 1654
34. N.J. Combates, P.O. Kwon, R.W. Rzepka, and D. Cohen Involvement of the transcription factor NF-IL6 in phorbol ester induction of P-glycoprotein in U937 cells Cell Growth Differ. 8 2 1997 213 219
35. M. Cvetkovic, B. Leake, M.F. Fromm, G.R. Wilkinson, and R.B. Kim OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine Drug Metab. Dispos. 27 8 1999 866 871
36. M. Dannawi Possible serotonin syndrome after combination of buspirone and St. John's wort J. Psychopharmacol. 16 4 2002 401
37. A. Dasgupta Review of abnormal laboratory test results and toxic effects due to use of herbal medicines Am.J. Clin. Pathol. 120 1990 127 137
38. C.J. Decker, L.M. Laitinen, G.W. Bridson, S.A. Raybuck, R.D. Tung, and P.R. Chaturvedi Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions J. Pharm. Sci. 87 7 1998 803 807
39. R.G. Deeley, and S.P. Cole Function, evolution and structure of multidrug resistance protein (MRP) Semin. Cancer Biol. 8 3 1997 193 204
40. D. Dittmer, S. Pati, G. Zambetti, S. Chu, A.K. Teresky, M. Moore, C. Finlay, and A.J. Levine Gain of function mutations in p53 Nat. Genet. 4 1 1993 42 46
41. S. Drescher, H. Glaeser, T. Murdter, M. Hitzl, M. Eichelbaum, and M.F. Fromm P-glycoprotein-mediated intestinal and biliary digoxin transport in humans Clin. Pharmacol. Ther. 73 3 2003 223 231
42. G.K. Dresser, U.I. Schwarz, G.R. Wilkinson, and R.B. Kim Coordinate induction of both cytochrome P4503A and MDR1 by St. John's wort in healthy subjects Clin. Pharmacol. Ther. 73 1 2003 41 50
43. D. Durr, B. Stieger, G.A. Kullak-Ublick, K.M. Rentsch, H.C. Steinert, P.J. Meier, and K. Fattinger St. John's wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4 Clin. Pharmacol. Ther. 68 6 2000 598 604
44. D. Durr, B. Stieger, G.A. Kullak-Ublick, K.M. Rentsch, H.C. Steinert, P.J. Meier, and K. Fattinger St. John's wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4 Clin. Pharmacol. Ther. 68 6 2000 598 604 (t and artType = abs and id = a112240 and target = )
45. D.M. Eisenberg, T.J. Kaptchuk, C. Laine, and F. Davidoff Complementary and alternative medicine-an Annals series Ann. Intern. Med. 135 3 2001 208
46. E. Ernst Harmless herbs? A review of the recent literature Am. J. Med. 104 2 1998 170 178
47. E. Ernst Second thoughts about safety of St. John's wort Lancet 354 9195 1999 2014 2016
48. A.M. Evans Influence of dietary components on the gastrointestinal metabolism and transport of drugs Ther. Drug Monit. 22 1 2000 131 136
49. B.L. Fiebich, A. Hollig, and K. Lieb Inhibition of substance P-induced cytokine synthesis by St. John's wort extracts Pharmacopsychiatry 34 Suppl. 1 2001 S26 S28
50. M.E. Fitzsimmons, and J.M. Collins Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism Drug Metab. Dispos. 25 2 1997 256 266
51. A. Fugh-Berman Herb-drug interactions Lancet 355 9198 2000 134 138
52. A. Fugh-Berman, and E. Ernst Herb-drug interactions: review and assessment of report reliability Br. J. Clin. Pharmacol.Vol nr 52 5 2001 587 595
53. U. Fuhr Drug interactions with grapefruit juice. Extent, probable mechanism and clinical relevance Drug Safety 18 4 1998 251 272
54. J. Gaedeke, L.M. Fels, C. Bokemeyer, U. Mengs, H. Stolte, and H. Lentzen Cisplatin nephrotoxicity and protection by silibinin Nephrol. Dial. Transplant. 11 1 1996 55 62
55. K. Gallicano, B. Foster, and S. Choudhri Effect of short-term administration of garlic supplements on single-dose ritonavir pharmacokinetics in healthy volunteers Br. J. Clin. Pharmacol. 55 2 2003 199 202
56. B. Goodwin, L.B. Moore, C.M. Stoltz, D.D. McKee, and S.A. Kliewer Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor Mol. Pharmacol. 60 3 2001 427 431
57. J.B. Gordon SSRIs and St. John's wort: possible toxicity? Am. Fam. Phys. 57 5 1998 950 953
58. M.M. Gottesman, and I. Pastan Biochemistry of multidrug resistance mediated by the multidrug transporter Annu. Rev. Biochem. 62 1993 385 427
59. F.P. Guengerich, M.V. Martin, P.H. Beaune, P. Kremers, T. Wolff, and D.J. Waxman Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism J. Biol. Chem. 261 11 1986 5051 5060
60. L.Q. Guo, M. Taniguchi, Y.Q. Xiao, K. Baba, T. Ohta, and Y. Yamazoe Inhibitory effect of natural furanocoumarins on human microsomal cytochrome P450 3A activity Jpn. J. Pharmacol. 82 2 2000 122 129
61. H.R. Ha, J. Chen, A.U. Freiburghaus, and F. Follath Metabolism of theophylline by cDNA-expressed human cytochromes P-450 Br. J. Clin. Pharmacol. 39 3 1995 321 326
62. C. Handschin, and U.A. Meyer Induction of drug metabolism: the role of nuclear receptors Pharmacol. Rev. 55 4 2003 649 673
63. J. Harenberg, C. Giese, and R. Zimmermann Effect of dried garlic on blood coagulation, fibrinolysis, platelet aggregation and serum cholesterol levels in patients with hyperlipoproteinemia Atherosclerosis 74 3 1988 247 249
64. M. Hennessy, D. Kelleher, J.P. Spiers, M. Barry, P. Kavanagh, D. Back, F. Mulcahy, and J. Feely St Johns wort increases expression of P-glycoprotein: implications for drug interactions Br. J. Clin. Pharmacol. 53 1 2002 75 82
65. A. Hsu, G.R. Granneman, and R.J. Bertz Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents Clin. Pharmacokinet. 35 4 1998 275 291
66. S.C. Hyde, P. Emsley, M.J. Hartshorn, M.M. Mimmack, U. Gileadi, S.R. Pearce, M.P. Gallagher, D.R. Gill, R.E. Hubbard, and C.F. Higgins Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport Nature 346 6282 1990 362 365
67. C. Ioannides Pharmacokinetic interactions between herbal remedies and medicinal drugs Xenobiotica 32 6 2002 451 478
68. K. Ito, T. Iwatsubo, S. Kanamitsu, K. Ueda, H. Suzuki, and Y. Sugiyama Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver Pharmacol. Rev. 50 3 1998 387 412
69. A.A. Izzo, and E. Ernst Interactions between herbal medicines and prescribed drugs: a systematic review Drugs 61 15 2001 2163 2175
70. K. Janetzky, and A.P. Morreale Probable interaction between warfarin and ginseng Am. J. Health-Syst. Pharm. 54 6 1997 692 693
71. A. Johne, J. Brockmoller, S. Bauer, A. Maurer, M. Langheinrich, and I. Roots Pharmacokinetic interaction of digoxin with an herbal extract from St. John's wort (Hypericum perforatum) Clin. Pharmacol. Ther. 66 4 1999 338 345
72. A. Johne, J. Schmider, J. Brockmoller, A.M. Stadelmann, E. Stormer, S. Bauer, G. Scholler, M. Langheinrich, and I. Roots Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John's wort (Hypericum perforatum) J. Clin. Psychopharmacol. 22 1 2002 46 54
73. J.W. Jonker, J.W. Smit, R.F. Brinkhuis, M. Maliepaard, J.H. Beijnen, J.H. Schellens, and A.H. Schinkel Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan J. Natl. Cancer Inst. 92 20 2000 1651 1656
74. R.L. Juliano, and V. Ling A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants Biochim. Biophys. Acta 455 1 1976 152 162
75. L.S. Kaminsky, and Z.Y. Zhang Human P450 metabolism of warfarin Pharmacol. Ther. 73 1 1997 67 74
76. M. Karliova, U. Treichel, M. Malago, A. Frilling, G. Gerken, and C.E. Broelsch Interaction of Hypericum perforatum (St. John's wort) with cyclosporin A metabolism in a patient after liver transplantation J. Hepatol. 33 5 2000 853 855
77. M. Katoh, M. Nakajima, H. Yamazaki, and T. Yokoi Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport Eur. J. Pharm. Sci. 12 4 2001 505 513
78. A. Kawaguchi, M. Ohmori, S. Tsuruoka, K. Nishiki, K. Harada, I. Miyamori, R. Yano, T. Nakamura, M. Masada, and A. Fujimura Drug interaction between St. John's wort and quazepam Br. J. Clin. Pharmacol. 58 4 2004 403 410
79. A.D. Kaye, R.C. Clarke, R. Sabar, S. Vig, K.P. Dhawan, R. Hofbauer, and A.M. Kaye Herbal medicines: current trends in anesthesiology practice-a hospital survey J. Clin. Anesth. 12 6 2000 468 471
80. B.M. Kerr, K.E. Thummel, C.J. Wurden, S.M. Klein, D.L. Kroetz, F.J. Gonzalez, and R.H. Levy Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation Biochem. Pharmacol. 47 11 1994 1969 1979
81. R.C. Kessler, R.B. Davis, D.F. Foster, M.I. Van Rompay, E.E. Walters, S.A. Wilkey, T.J. Kaptchuk, and D.M. Eisenberg Long-term trends in the use of complementary and alternative medical therapies in the United States Ann. Intern. Med. 135 4 2001 262 268
82. A.E. Kim, J.M. Dintaman, D.S. Waddell, and J.A. Silverman Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein J. Pharmacol. Exp. Ther. 286 3 1998 1439 1445
83. H. Kipp, and I.M. Arias Intracellular trafficking and regulation of canalicular ATP-binding cassette transporters Semin. Liver Dis. 20 3 2000 339 351
84. J.C. Kolars, P. Schmiedlin-Ren, J.D. Schuetz, C. Fang, and P.B. Watkins Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes J. Clin. Invest. 90 5 1992 1871 1878
85. T. Kronbach, V. Fischer, and U.A. Meyer Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs Clin. Pharmacol. Ther. 43 6 1988 630 635
86. G.N. Kumar, A.D. Rodrigues, A.M. Buko, and J.F. Denissen Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes J. Pharmacol. Exp. Ther. 277 1 1996 423 431
87. B. Lacarelle, R. Rahmani, G. de Sousa, A. Durand, M. Placidi, and J.P. Cano Metabolism of digoxin, digoxigenin digitoxosides and digoxigenin in human hepatocytes and liver microsomes Fundam. Clin. Pharmacol. 5 7 1991 567 582
88. M.S. Lantz, E. Buchalter, and V. Giambanco St. John's wort and antidepressant drug interactions in the elderly J. Geriatr. Psychiatry Neurol. 12 1 1999 7 10
89. V. Lecureur, D. Sun, P. Hargrove, E.G. Schuetz, R.B. Kim, L.B. Lan, and J.D. Schuetz Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein Mol. Pharmacol. 57 1 2000 24 35
90. F.C. Lee, J.H. Ko, J.K. Park, and J.S. Lee Effects of Panax ginseng on blood alcohol clearance in man Clin. Exp. Pharmacol. Physiol. 14 6 1987 543 546
91. C. Legnani, M. Frascaro, G. Guazzaloca, S. Ludovici, G. Cesarano, and S. Coccheri Effects of a dried garlic preparation on fibrinolysis and platelet aggregation in healthy subjects Arzneimittelforschung 43 2 1993 119 122
92. E.M. Leslie, R.G. Deeley, and S.P. Cole Toxicological relevance of the multidrug resistance protein 1 MRP1 (ABCC1) and related transporters Toxicology 167 1 2001 3 23
93. X. Li, and W.K. Chan Transport, metabolism and elimination mechanisms of anti-HIV agents Adv. Drug Deliv. Rev. 39 1-3 1999 81 103
94. J.H. Lin, and M. Yamazaki Role of P-glycoprotein in pharmacokinetics: clinical implications Clin. Pharmacokinet. 42 1 2003 59 98
95. T. Litman, T.E. Druley, W.D. Stein, and S.E. Bates From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance Cell. Mol. Life Sci. 58 7 2001 931 959
96. F.R. Luo, P.V. Paranjpe, A. Guo, E. Rubin, and P. Sinko Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1 Drug Metab. Dispos. 30 7 2002 763 770
97. L.I. Malaty, and J.J. Kuper Drug interactions of HIV protease inhibitors Drug Safety 20 2 1999 147 169
98. J.S. Markowitz, C.L. DeVane, D.W. Boulton, S.W. Carson, Z. Nahas, and S.C. Risch Effect of St. John's wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers Life Sci. 66 9 2000 PL133 PL139
99. R.H. Mathijssen, J. Verweij, P. de Bruijn, W.J. Loos, and A. Sparreboom Effects of St. John's wort on irinotecan metabolism J. Natl. Cancer Inst. 94 16 2002 1247 1249
100. A.J.A. Mauer, and S. Bauer Interaction of St. John's wort extract with phenprocoumon Eur. J. Clin. Pharmacol. 55 1999 A22
101. A.K. Mitra, and J. Patel Strategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs Pharmacogenomics 2 4 2001 401 415
102. M. Miyazaki, K. Kohno, T. Uchiumi, H. Tanimura, K. Matsuo, M. Nasu, and M. Kuwano Activation of human multidrug resistance-1 gene promoter in response to heat shock stress Biochem. Biophys. Res. Commun. 187 2 1992 677 684
103. D.E. Moody, M.E. Alburges, R.J. Parker, J.M. Collins, and J.M. Strong The involvement of cytochrome P450 3A4 in the N-demethylation of l-alpha-acetylmethadol (LAAM), norLAAM, and methadone Drug Metab. Dispos. 25 12 1997 1347 1353
104. L.B. Moore, B. Goodwin, S.A. Jones, G.B. Wisely, C.J. Serabjit-Singh, T.M. Willson, J.L. Collins, and S.A. Kliewer St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor Proc. Natl. Acad. Sci. U. S. A. 97 13 2000 7500 7502
105. P. Muriel, T. Garciapina, V. Perez-Alvarez, and M. Mourelle Silymarin protects against paracetamol-induced lipid peroxidation and liver damage J. Appl. Toxicol. 12 6 1992 439 442
106. A. Nebel, B.J. Schneider, R.K. Baker, and D.J. Kroll Potential metabolic interaction between St. John's wort and theophylline Ann. Pharmacother. 33 4 1999 502
107. R.S. Obach Inhibition of human cytochrome P450 enzymes by constituents of St. John's wort, an herbal preparation used in the treatment of depression J. Pharmacol. Exp. Ther. 294 1 2000 88 95
108. B. Ogretmen, and A.R. Safa Identification and characterization of the MDR1 promoter-enhancing factor 1 (MEF1) in the multidrug resistant HL60/VCR human acute myeloid leukemia cell line Biochemistry 39 1 2000 194 204
109. O.V. Olesen, and K. Linnet Metabolism of the tricyclic antidepressant amitriptyline by cDNA-expressed human cytochrome P450 enzymes Pharmacology 55 5 1997 235 243
110. V. Parker, A.H. Wong, H.S. Boon, and M.V. Seeman Adverse reactions to St. John's wort Can. J. Psychiatry 46 1 2001 77 79
111. A. Parkinson An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials Toxicol. Pathol. 24 1 1996 48 57
112. J. Patel, B. Buddha, S. Dey, D. Pal, and A.K. Mitra In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity Am. J. Ther. 11 4 2004 262 277
113. J. Patel, and A.K. Mitra Strategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs Pharmacogenomics 2 4 2001 401 415
114. C.C. Paulusma, P.J. Bosma, G.J. Zaman, C.T. Bakker, M. Otter, G.L. Scheffer, R.J. Scheper, P. Borst, and R.P. Oude Elferink Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene Science 271 5252 1996 1126 1128
115. C.C. Paulusma, M. Kool, P.J. Bosma, G.L. Scheffer, F. ter Borg, R.J. Scheper, G.N. Tytgat, P. Borst, F. Baas, and R.P. Oude Elferink A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome Hepatology 25 6 1997 1539 1542
116. M.D. Perloff, L.L. von Moltke, E. Stormer, R.I. Shader, and D.J. Greenblatt Saint John's wort: an in vitro analysis of P-glycoprotein induction due to extended exposure Br. J. Pharmacol. 134 8 2001 1601 1608
117. S.C. Piscitelli, A.H. Burstein, D. Chaitt, R.M. Alfaro, and J. Falloon Indinavir concentrations and St. John's wort Lancet 355 9203 2000 547 548
118. S.C. Piscitelli, A.H. Burstein, N. Welden, K.D. Gallicano, and J. Falloon The effect of garlic supplements on the pharmacokinetics of saquinavir Clin. Infect. Dis. 34 2 2002 234 238
119. S.C. Piscitelli, E. Formentini, A.H. Burstein, R. Alfaro, S. Jagannatha, and J. Falloon Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers Pharmacotherapy 22 5 2002 551 556
120. T. Prueksaritanont, L.M. Gorham, B. Ma, L. Liu, X. Yu, J.J. Zhao, D.E. Slaughter, B.H. Arison, and K.P. Vyas In vitro metabolism of simvastatin in humans [SBT] identification of metabolizing enzymes and effect of the drug on hepatic P450s Drug Metab. Dispos. 25 10 1997 1191 1199
121. J.M. Rey, and G. Walter Hypericum perforatum (St. John's wort) in depression: pest or blessing? Med. J. Aust. 169 11-12 1998 583 586
122. C.A. Roby, G.D. Anderson, E. Kantor, D.A. Dryer, and A.H. Burstein St. John's wort: effect on CYP3A4 activity Clin.Pharmacol. Ther. 67 5 2000 451 457
123. I. Roots Drug interactions with Hypericum. Is nature not so mild after all? Interview by Petra Eiden MMW Fortschr. Med. 142 2000 14
124. K.D. Rose, P.D. Croissant, C.F. Parliament, and M.B. Levin Spontaneous spinal epidural hematoma with associated platelet dysfunction from excessive garlic ingestion: a case report Neurosurgery 26 1990 880 882
125. M. Rosenblatt, and J. Mindel Spontaneous hyphema associated with ingestion of Ginkgo biloba extract N. Engl. J. Med. 336 1997 1108
126. F. Ruschitzka, P.J. Meier, M. Turina, T.F. Luscher, and G. Noll Acute heart transplant rejection due to Saint John's wort Lancet 355 9203 2000 548 549
127. A. Santos, S. Zanetta, T. Cresteil, A. Deroussent, F. Pein, E. Raymond, L. Vernillet, M.L. Risse, V. Boige, A. Gouyette, and G. Vassal Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans Clin. Cancer Res. 6 5 2000 2012 2020
128. M.A. Sarkar, C. Hunt, P.S. Guzelian, and H.T. Karnes Characterization of human liver cytochromes P-450 involved in theophylline metabolism Drug Metab. Dispos. 20 1 1992 31 37
129. F. Scaglione, G. Cattaneo, M. Alessandria, and R. Cogo Efficacy and safety of the standardised ginseng extract G115 for potentiating vaccination against the influenza syndrome and protection against the common cold [corrected] Drugs Exp. Clin. Res. 22 2 1996 65 72
130. F. Scaglione, F. Ferrara, S. Dugnani, M. Falchi, G. Santoro, and F. Fraschini Immunomodulatory effects of two extracts of Panax ginseng C.A. Meyer Drugs Exp. Clin. Res. 16 10 1990 537 542
131. G. Scambia, F.O. Ranelletti, P.B. Panici, R. De Vincenzo, G. Bonanno, G. Ferrandina, M. Piantelli, S. Bussa, C. Rumi, and M. Cianfriglia Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target Cancer Chemother. Pharmacol. 34 6 1994 459 464
132. A.H. Schinkel, E. Wagenaar, L. van Deemter, C.A. Mol, and P. Borst Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A J. Clin. Invest. 96 4 1995 1698 1705
133. K.W. Scotto, and R.A. Johnson Transcription of the multidrug resistance gene MDR1: a therapeutic target Mol. Interv. 1 2 2001 117 125
134. A.B. Shapiro, and V. Ling Effect of quercetin on Hoechst 33342 transport by purified and reconstituted P-glycoprotein Biochem. Pharmacol. 53 4 1997 587 596
135. F.J. Sharom The P-glycoprotein efflux pump: how does it transport drugs? J. Membr. Biol. 160 3 1997 161 175
136. C.P. Siegers, A. Fruhling, and M. Younes Influence of dithiocarb, (+)-catechin and silybine on halothane hepatotoxicity in the hypoxic rat model Acta Pharm. Toxicol. (Copenh.) 53 1983 125 129
137. E.A. Sotaniemi, E. Haapakoski, and A. Rautio Ginseng therapy in non-insulin-dependent diabetic patients Diabetes Care 18 10 1995 1373 1375
138. M. Spinella, and L.A. Eaton Hypomania induced by herbal and pharmaceutical psychotropic medicines following mild traumatic brain injury Brain Inj. 16 4 2002 359 367
139. T.W. Synold, I. Dussault, and B.M. Forman The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux Nat. Med. 7 5 2001 584 590
140. F. Thiebaut, T. Tsuruo, H. Hamada, M.M. Gottesman, I. Pastan, and M.C. Willingham Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues Proc. Natl. Acad. Sci. U. S. A. 84 21 1987 7735 7738
141. J.V. Thottassery, G.P. Zambetti, K. Arimori, E.G. Schuetz, and J.D. Schuetz p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents Proc. Natl. Acad. Sci. U. S. A. 94 20 1997 11037 11042
142. K.E. Thummel, and G.R. Wilkinson In vitro and in vivo drug interactions involving human CYP3A Annu. Rev. Pharmacol. Toxicol. 38 1998 389 430
143. R. Tian, N. Koyabu, H. Takanaga, H. Matsuo, H. Ohtani, and Y. Sawada Effects of grapefruit juice and orange juice on the intestinal efflux of P-glycoprotein substrates Pharm. Res. 19 6 2002 802 809
144. K. Ueda, C. Cardarelli, M.M. Gottesman, and I. Pastan Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine Proc. Natl. Acad. Sci. U. S. A. 84 9 1987 3004 3008
145. A. van Helvoort, A.J. Smith, H. Sprong, I. Fritzsche, A.H. Schinkel, P. Borst, and G. van Meer MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine Cell 87 3 1996 507 517
146. S. Vella, and M. Floridia Saquinavir. Clinical pharmacology and efficacy Clin. Pharmacokinet. 34 3 1998 189 201
147. K. Venkatakrishnan, D.J. Greenblatt, L.L. von Moltke, J. Schmider, J.S. Harmatz, and R.I. Shader Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP 2C19 and 3A4 J. Clin. Pharmacol. 38 2 1998 112 121
148. K. Venkatakrishnan, L.L. von Moltke, and D.J. Greenblatt Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs J. Clin. Pharmacol. 39 6 1999 567 577
149. K. Venkatakrishnan, J. Schmider, J.S. Harmatz, B.L. Ehrenberg, L.L. von Moltke, J.A. Graf, P. Mertzanis, K.E. Corbett, M.C. Rodriguez, R.I. Shader, and D.J. Greenblatt Relative contribution of CYP3A to amitriptyline clearance in humans: in vitro and in vivo studies J. Clin. Pharmacol. 41 10 2001 1043 1054
150. J. von Schonfeld, B. Weisbrod, and M.K. Muller Silibinin, a plant extract with antioxidant and membrane stabilizing properties, protects exocrine pancreas from cyclosporin A toxicity Cell Mol. Life Sci. 53 1997 917 920
151. V. Vuksan, J.L. Sievenpiper, V.Y. Koo, T. Francis, U. Beljan-Zdravkovic, Z. Xu, and E. Vidgen American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus Arch. Intern. Med. 160 7 2000 1009 1013
152. V.J. Wacher, L. Salphati, and L.Z. Benet Active secretion and enterocytic drug metabolism barriers to drug absorption Adv. Drug Deliv. Rev. 46 1-3 2001 89 102
153. V.J. Wacher, J.A. Silverman, Y. Zhang, and L.Z. Benet Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics J. Pharm. Sci. 87 11 1998 1322 1330
154. V.J. Wacher, C.Y. Wu, and L.Z. Benet Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy Mol. Carcinog. 13 3 1995 129 134
155. Z. Wang, J.C. Gorski, M.A. Hamman, S.M. Huang, L.J. Lesko, and S.D. Hall The effects of St. John's wort (Hypericum perforatum) on human cytochrome P450 activity Clin. Pharmacol. Ther. 70 4 2001 317 326
156. Z. Wang, M.A. Hamman, S.M. Huang, L.J. Lesko, and S.D. Hall Effect of St. John's wort on the pharmacokinetics of fexofenadine Clin. Pharmacol. Ther. 71 6 2002 414 420
157. C.B. Washington, G.E. Duran, M.C. Man, B.I. Sikic, and T.F. Blaschke Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells J. Acquir. Immune Defic. Syndr. Human Retrovirol. 19 3 1998 203 209
158. P.B. Watkins The barrier function of CYP3A4 and P-glycoprotein in the small bowel Adv. Drug Deliv. Rev. 27 2-3 1997 161 170
159. P.B. Watkins, S.A. Wrighton, E.G. Schuetz, D.T. Molowa, and P.S. Guzelian Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man J. Clin. Invest. 80 4 1987 1029 1036
160. R.S. Weinstein, J.R. Kuszak, L.F. Kluskens, and J.S. Coon P-glycoproteins in pathology: the multidrug resistance gene family in humans Hum. Pathol. 21 1 1990 34 48
161. J.M. Wentworth, M. Agostini, J. Love, J.W. Schwabe, and V.K. Chatterjee St. John's wort, a herbal antidepressant, activates the steroid X receptor J. Endocrinol. 166 3 2000 R11 R16
162. G.R. Wilkinson The effects of diet, aging and disease-states on presystemic elimination and oral drug bioavailability in humans Adv. Drug Deliv. Rev. 27 2-3 1997 129 159
163. G.C. Williams, and P.J. Sinko Oral absorption of the HIV protease inhibitors: a current update Adv. Drug Deliv. Rev. 39 1-3 1999 211 238
164. D.K. Yu The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions J. Clin. Pharmacol. 39 12 1999 1203 1211
165. Q.Y. Yue, C. Bergquist, and B. Gerden Safety of St. John's wort (Hypericum perforatum) Lancet 355 9203 2000 576 577
166. R.L. Zastawny, R. Salvino, J. Chen, S. Benchimol, and V. Ling The core promoter region of the P-glycoprotein gene is sufficient to confer differential responsiveness to wild-type and mutant p53 Oncogene 8 6 1993 1529 1535
167. S. Zhang, X. Yang, and M.E. Morris Combined effects of multiple flavonoids on breast cancer resistance protein (ABCG2)-mediated transport Pharm. Res. 21 7 2004 1263 1273
168. D.C. Zhou, J.P. Marie, L. Maisonneuve, A.M. Faussat-Suberville, and R. Zittoun Effect of differentiating agents on modulation of MDR1 gene expression in multidrug-resistant hematopoietic HL60/DNR cell line Exp. Hematol. 21 6 1993 779 784
169. S. Zhou, E. Chan, S.Q. Pan, M. Huang, and E.J. Lee Pharmacokinetic interactions of drugs with St. John's wort J. Psychopharmacol. 18 2 2004 262 276
170. S. Zhou, J.D. Schuetz, K.D. Bunting, A.M. Colapietro, J. Sampath, J.J. Morris, I. Lagutina, G.C. Grosveld, M. Osawa, H. Nakauchi, and B.P. Sorrentino The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype Nat. Med. 7 9 2001 1028 1034
171. T. Zima, L. Kamenikova, M. Janebova, E. Buchar, J. Crkovska, and V. Tesar The effect of silibinin on experimental cyclosporine nephrotoxicity Ren. Fail. 20 13 1998 471 479
172. L. Zou, M.R. Harkey, and G.L. Henderson Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity Life Sci. 71 13 2002 1579 1589